George M. Tsoukas, MD, FRCPC
Associate Professor, Department of Medicine
Tel: 514-934-1934 ext. 44221
g.tsoukas [at] gmail.com
George M. Tsoukas is a senior endocrinologist at the McGill University Health Centre. He was born in Castoria, Greece. Prior to his medical studies, he obtained a degree in fine arts and went on to graduate in honours biochemistry. He received his medical degree from McGill University. After finishing his postgraduate training in Internal Medicine, Dr. Tsoukas completed a fellowship in Endocrinology and Metabolism. He is now on staff at the MUHC where he teaches and carries on clinical research.
Dr. Tsoukas’ medical and research discipline include the molecular biology and the endocrinology of bone and diabetes. He has authored numerous papers, particularly in the treatment of Paget’s disease of bone. He is a fellow of the Royal Canadian College of Physicians and also a member of a number of professional societies including the American Society for Bone and Mineral Research and the American Heart Association. As researcher at the McGill Musculoskeletal Axis, Dr. Tsoukas is involved with major clinical trials in the area of osteoporosis and has led several osteoporosis clinics.
Clinics, osteoporosis, diabetes mellitus, clinical trials, teaching
Research or Clinical Activities
Dr. Tsoukas currently participates in 5 clinics at the MUHC. His clinical activities consist of active patient care along with teaching medical students and residents. Currently he is conducting numerous clinical trials, including attempts at restoring beta-cell function in type 1 and type 2 diabetes. His research also extends into the field of osteoporosis, where he lectures on novel therapeutics on a local and international level.
Selected Recent Publications
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28.
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012 Jul 26;367(4):309-18.
Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes: An analysis of baseline data from the ORIGIN trial. Diabetes Care. 2012 Apr;35(4):749-753.
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012 Jun;35(6):1225-31.